Avinger, Inc. (NASDAQ:AVGR) Short Interest Down 39.5% in November

Avinger, Inc. (NASDAQ:AVGR) was the target of a significant decline in short interest during the month of November. As of November 15th, there was short interest totalling 65,000 shares, a decline of 39.5% from the October 31st total of 107,400 shares. Based on an average daily trading volume, of 227,300 shares, the days-to-cover ratio is presently 0.3 days. Currently, 2.4% of the company’s stock are short sold.

Avinger Stock Up 0.9 %

Shares of Avinger stock traded up $0.01 on Friday, reaching $0.84. The company’s stock had a trading volume of 14,313 shares, compared to its average volume of 94,880. Avinger has a 52 week low of $0.70 and a 52 week high of $5.45. The company has a market capitalization of $2.69 million, a price-to-earnings ratio of -0.08 and a beta of 1.15. The firm’s fifty day simple moving average is $0.88 and its two-hundred day simple moving average is $1.41.

Avinger (NASDAQ:AVGR) last announced its quarterly earnings data on Thursday, November 7th. The medical device company reported ($1.82) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.03) by $0.21. Avinger had a negative return on equity of 5,527.11% and a negative net margin of 261.06%. The company had revenue of $1.65 million for the quarter, compared to analysts’ expectations of $1.60 million. During the same quarter in the prior year, the firm earned ($2.92) earnings per share. As a group, research analysts predict that Avinger will post -4.69 EPS for the current year.

Institutional Trading of Avinger

An institutional investor recently bought a new position in Avinger stock. Armistice Capital LLC bought a new position in shares of Avinger, Inc. (NASDAQ:AVGR) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 43,747 shares of the medical device company’s stock, valued at approximately $81,000. Armistice Capital LLC owned 2.57% of Avinger as of its most recent SEC filing. 18.30% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, StockNews.com assumed coverage on Avinger in a research note on Tuesday. They set a “hold” rating for the company.

Avinger Company Profile

Avinger, Inc, a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.